IY7 Stock Overview
Focuses on mental health and sexual wellness by licensing and distributing psychedelic and hemp–infused products in North America, the United Kingdom, and Europe.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Jolt Health Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.0005 |
| 52 Week High | CA$0.014 |
| 52 Week Low | CA$0.0005 |
| Beta | 1.49 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -92.31% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| IY7 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.7% | 1.1% |
| 1Y | -92.3% | -21.6% | 6.5% |
Return vs Industry: IY7 underperformed the German Pharmaceuticals industry which returned -21.6% over the past year.
Return vs Market: IY7 underperformed the German Market which returned 6.5% over the past year.
Price Volatility
| IY7 volatility | |
|---|---|
| IY7 Average Weekly Movement | 0% |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: IY7 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine IY7's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Gerald Tritt | jolt-health.com |
Jolt Health Inc. focuses on mental health and sexual wellness by licensing and distributing psychedelic and hemp–infused products in North America, the United Kingdom, and Europe. It offers BLOOM, a topical clitoral stimulation gel; and AURALIEF, a hemp-infused sublingual strip. The company was formerly known as Love Pharma Inc. and changed its name to Jolt Health Inc. in May 2023.
Jolt Health Inc. Fundamentals Summary
| IY7 fundamental statistics | |
|---|---|
| Market cap | €430.36k |
| Earnings (TTM) | -€517.78k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.8x
P/E RatioIs IY7 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IY7 income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$765.74k |
| Earnings | -CA$765.73k |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.006 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did IY7 perform over the long term?
See historical performance and comparison